Health providers, especially in the U.S., are consolidating, so Boston Sci needs to persuade hospital system officials that their products are the best in particular areas. “Category leadership is everything. Hospitals – whether you’re in Korea or St. Paul – they want innovation at low cost,” Mahoney said today at Healthegy’s Medtech Conference in Minneapolis.
Boston Scientific, for example, is making a big bet on structural heart devices. The company recently boasted that its Lotus TAVR, with its Chinese-finger-trap-like design, beat Medtronic’s CoreValve in a head-to-head trial. Boston Sci doubled down on TAVR by paying $435 million for Symetis and its line of minimally invasive replacement heart valves. And the company continues to report positive results for its Watchman left atrial appendage closure device.
Mahoney sees a multibillion-dollar market for Boston Scientific in the structural heart space.
“We’re not the biggest company, so we have to be category leaders,” Mahoney said.
Get the full story on our sister site, Medical Design & Outsourcing.
The post Here is Boston Scientific’s plan to win in medtech appeared first on MassDevice.
from MassDevice http://ift.tt/2qFDYJ5
Cap comentari:
Publica un comentari a l'entrada